Grace Therapeutics: Opaleye Management buys 60,490 shares

Opaleye Management, a 10% owner of Grace Therapeutics, increased its stake through open-market purchases of 60,490 shares at weighted-average prices of $2.0353, $2.0684, and $2.06. Reported ownership rose to 2,858,657 shares.